title: Duration of trastuzumab for HER2-positive breast cancer.
authors.affiliation: Unit of Investigative Clinical Oncology, Piedmont Oncology Foundation, Institute for Cancer Research and Treatment, Strada Provinciale 142, Km 3.95 - 10060, Candiolo, Italy. filippo.montemurro@ircc.it
authors.forename: Filippo
authors.initials: F
authors.lastname: Montemurro
authors.forename: Massimo
authors.initials: M
authors.lastname: Aglietta
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D006801:Humans; D008408:Mastectomy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human